A phase 1/2 clinical trial examining the CRISPR-engineered allogeneic chimeric antigen receptor (CAR)-T candidate AVC-203 (QUADvance) has been approved by the FDA and the European Medicines Agency ...
Please provide your email address to receive an email when new articles are posted on . A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the ...
Erythropoietin, the protein that drives red blood cell formation, also induces tolerance in dendritic cells, leading to the ...
DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients ...
The researchers argue that their findings, published in Scientific Reports, could help clinicians anticipate which patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback